Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS

    Andrea Cignarella, Roberto Mioni, Chiara Sabbadin, Francesca Dassie, Matteo Parolin, Roberto Vettor, Mattia Barbot, Carla Scaroni
    TLDR Treatments for PCOS aim to reduce androgen levels and improve insulin sensitivity to lower cardiometabolic risk.
    The review discussed various pharmacological approaches to managing cardiometabolic risk in women with PCOS, emphasizing the role of hyperandrogenism and insulin resistance. Treatments included antiandrogens like flutamide and spironolactone, which improved symptoms such as hirsutism and insulin resistance. Metformin and inositols were effective in improving insulin sensitivity and metabolic profiles. Combined oral contraceptives were used for androgen-related symptoms but carried risks like thromboembolic events. The review highlighted the importance of individualized treatment plans and lifestyle changes, noting the need for further research to optimize therapy and understand long-term effects.
    Discuss this study in the Community →

    Research cited in this study

    21 / 21 results